natgillin/translations-raw huggingface dataset:
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age 75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction <45%; or documented peripheral vascular disease. 
V program ACTIVE so bili randomizirani bolniki, ki so imeli dokumentirano AF, tj. bodisi permanentno AF ali vsaj 2 epizodi intermitentne AF v zadnjih 6 mesecih ter vsaj enega od naslednjih dejavnikov tveganja: starost  75 let ali starost od 55 do 74 let in bodisi sladkorno bolezen, ki je zahtevala zdravljenje z zdravili, ali dokumentiran predhodni MI ali dokumentirano koronarno bolezen; zdravljenje zaradi sistemske hipertenzije; predhodno možgansko kap, tranzitorno ishemično atako
Titanium dioxide (E171)Red iron oxide (E172) Yellow iron oxide (E172) Talc 
Filmska obloga: polivinilalkohol titanov dioksid (E171) rdeči železov oksid (E172) rumeni železov oksid (E172) smukec makrogol 3000
Because the active metabolite is formed by CYP450 enzymes, some of which are polymorphic or subject to inhibition by other medicinal products, not all patients will have adequate platelet inhibition. 
Ker aktivni presnovek nastane z delovanjem encimov CYP450, ki se razlikujejo med seboj po polimorfizmu ali pa jih lahko zavirajo druga zdravila, se ustrezno zavrtje agregacije trombocitov ne pojavi pri vseh bolnikih.
In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450. 
Tako in vitro kot in vivo se presnovi po dveh glavnih presnovnih poteh: ena poteka z esterazami kjer s hidrolizo nastane neaktiven karboksilnokislinski derivat (85 % presnovkov v obtoku), druga pa prek encimov citokroma P450.
Then, the recommended dose is one 75 mg tablet of Clopidogrel Krka d.d. 
Priporočeni odmerek je ena 75 mg tableta zdravila Clopidogrel Krka d.d.
Headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness. 
Glavobol, razjeda na želodcu, bruhanje, slabost, zaprtost, preveč plinov v želodcu ali črevesju, izpuščaji, srbenje, omotica, občutek mravljinčenja in omrtvelosti.
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus 
bulozni dermatitis (toksična epidermalna nekroliza, StevensJohnsonov sindrom, multiformni eritem, akutna generalizirana eksantemska pustuloza (AGEP)), angioedem, z zdravili povzročen sindrom preobčutljivosti (sindrom DIHS, Drug-Induced Hypersensitivity Syndrome), kožni izpuščaj z eozinofilijo in sistemskimi simptomi, kot posledica zdravljenja z zdravilom (sindrom DRESS, Drug Rash with Eosinophilia and Systemic Symptoms), eritematozni ali eksfoliativen izpuščaj, urtikarija, ekcem, lihen planus
Patients on aspirin and a more potent P2Y12 blocker and without adverse event at one month were assigned to switch to fixed-dose aspirin plus clopidogrel (de-escalated dual antiplatelet therapy (DAPT)) or continuation of their drug regimen (unchanged DAPT). 
Bolnike, ki so prejemali acetilsalicilno kislino in močnejši blokator P2Y12 ter so bili po enem mesecu brez neželenih dogodkov, so razvrstili ali na prehod na kombinacijo fiksnih odmerkov acetilsalicilne kisline in klopidogrela (deeskalirano dvotirno antiagregacijsko zdravljenje (DAPT - de-escalated dual antiplatelet therapy) ali na nadaljevanje dotedanje sheme zdravljenja (nespremenjeno DAPT).
Caution is required in patients treated concomitantly with clopidogrel and CYP2C8 substrate medicinal products (see section 4.5). 
Previdnost je potrebna pri bolnikih, ki sočasno jemljejo klopidogrel in zdravila, ki so substrati CYP2C8 (glejte poglavje 4.5).
At steady state, the average inhibition level observed with a dose of 75 mg per day was between 40% and 60%. 
V stanju dinamičnega ravnovesja je bila povprečna raven zaviranja z odmerkom 75 mg na dan 40- do 60-odstotna.
The guided de-escalation did not result in an increased combined risk of ischemic events (2.5% in the deescalation group vs 3.2% in the control group; p non-inferiority=0.0115), nor in the key secondary endpoint of BARC bleeding ≥2 ((5%) in the de-escalation group versus 6% in the control group (p=0.23)). 
Vodena deeskalacija ni povečala ne kombiniranega tveganja za ishemične dogodke (2,5 % v skupini z deeskalacijo in 3,2 % v kontrolni skupini, p za neinferiornost = 0,0115) ne ključnega sekundarnega opazovanega dogodka, krvavitve ≥ 2 po BARC (5 % v skupini z deeskalacijo in 6 % v kontrolni skupini, p = 0,23).
Other medicinal products: 
Druga zdravila
What you need to know before you take Clopidogrel Krka d.d. 
Kaj morate vedeti, preden boste vzeli zdravilo Clopidogrel Krka d.d.
Therefore clopidogrel should be used with caution in these patients (see section 4.2). 
Zato moramo pri teh bolnikih klopidogrel uporabljati previdno (glejte poglavje 4.2).
The primary outcome, a composite of cardiovascular death, stroke, urgent revascularization, and BARC (Bleeding Academic Research Consortium) bleeding ≥2 at 1 year post ACS, occurred in 43 patients (13.4%) in the de-escalated DAPT group and in 85 patients (26.3%) in the unchanged DAPT group (p<0.01). 
Primarni izid, sestavljeni dogodek srčno-žilne smrti, možganske kapi, nujne revaskularizacije in krvavitve ≥ 2 po BARC (Bleeding Academic Research Consortium), se je 1 leto po AKS pojavil pri 43 bolnikih (13,4 %) v skupini z deeskaliranim DAPT in pri 85 bolnikih (26,3 %) v skupini z nespremenjenim DAPT (p < 0,01).
The CLARITY trial included 3,491 patients presenting within 12 hours of the onset of a ST elevation MI and planned for thrombolytic therapy. 
V študijo CLARITY je bilo v 12 urah po nastopu akutnega miokardnega infarkta z elevacijo ST-spojnice vključenih 3.491 bolnikov, ki so bili predvideni za trombolitično terapijo.
The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%). 
Zdravljenje s klopidogrelom v študiji CURE je bilo povezano z zmanjšano potrebo po zdravljenju s trombolitiki (zmanjšanje RT: 43,3 %; IZ: 24,3 %, 57,5 %) in zaviralci glikoproteinov IIb/IIIa (zmanjšanje RT: 18,2 %; IZ: 6,5 %, 28,3 %).
- carbamazepine a medicine to treat some forms of epilepsy, - moclobemide, medicine to treat depression, - repaglinide, medicine to treat diabetes, - paclitaxel, medicine to treat cancer, - anti-retroviral medicines (medicines to treat HIV infections). 
- moklobemid, zdravila za zdravljenje depresije, - repaglinid, zdravilo za zdravljenje sladkorne bolezni, - paklitaksel, zdravilo za zdravljenje raka, - protiretrovirusna zdravila (zdravila za zdravljenje okužbe z virusom HIV).
- If you have any further questions, ask your doctor or your pharmacist. 
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom.
Cellulose, microcrystalline Colloidal anhydrous silica Crospovidone (type A) Macrogol 6000 
Jedro tablete: celuloza, mikrokristalna brezvodni koloidni silicijev dioksid krospovidon (vrsta A) makrogol 6000 hidrogenirano ricinusovo olje
You should specifically tell your doctor if you take - medicines that may increase your risk of bleeding such as: o oral anticoagulants, medicines used to reduce blood clotting, o a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscle or joints, o heparin or any other injectable medicine used to reduce blood clotting, o ticlopidine, other antiplatelet agent, o a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression, - omeprazole or esomeprazole, medicines to treat upset stomach, - fluconazole or voriconazole, medicines to treat fungal infections, - efavirenz, a medicine to treat HIV (human immunodeficiency virus) infections, 
Še posebej pomembno je, da obvestite svojega zdravnika, če jemljete - zdravila, ki lahko povečajo tveganje za krvavitve, kot so: - peroralni antikoagulanti, zdravila, ki preprečujejo nastanek krvnih strdkov, - nesteroidna protivnetna zdravila, ki se običajno uporabljajo za lajšanje bolečine in/ali vnetja mišic ali sklepov, - heparin, ali katerokoli drugo zdravilo v obliki injekcij, ki se uporablja za zmanjševanje strjevanja krvi, - tiklopidin, druga antiagregacijska zdravila, - selektivni zaviralci privzema serotonina (vključno a ne omejeno na fluoksetin ali fluvoksamin), zdravila, ki se običajno uporabljajo za zdravljenje depresije, - omeprazol ali esomeprazol, zdravila za zdravljenje težav z želodcem, - flukonazol ali vorikonazol, zdravila za zdravljenje glivičnih okužb,
As a precaution, concomitant use of omeprazole or esomeprazole should be discouraged (see section 4.4). 
Zaradi previdnosti se je treba izogniti sočasni uporabi omeprazola ali esomeprazola (glejte poglavje 4.4).
Strokes occurred in 296 (7.8%) patients receiving clopidogrel + ASA and 408 (10.8%) patients receiving placebo + ASA (relative risk reduction, 28.4%; 95% CI, 16.8% to 38.3%; p=0.00001). 
Možganska kap se je pojavila pri 296 (7,8 %) bolnikih, ki so prejemali klopidogrel + ASA, in pri 408 (10,8 %) bolnikih, ki so prejemali placebo + ASA (relativno zmanjšanje tveganja 28,4 %, 95 % IZ: od 16,8 % do 38,3 %, p = 0,00001).
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia). 
Zlasti post hoc analiza podatkov 2.172 bolnikov (17 % celotne populacije študije CURE), ki so jim namestili žilno opornico (Stent-CURE), je ob zdravljenju s klopidogrelom v primerjavi s placebom pokazala značilno, 26,2-odstotno zmanjšanje RT za sestavljeni primarni opazovani dogodek (srčno-žilna smrt, MI, možganska kap) in tudi značilno, 23,9-odstotno zmanjšanje RT za drug sestavljeni primarni opazovani dogodek (srčno-žilna smrt, MI, možganska kap ali neodzivna ishemija).
Patients should be evaluated for history of hypersensitivity to thienopyridines (such as clopidogrel, ticlopidine, prasugrel) since cross-reactivity among thienopyridines has been reported (see section 4.8). 
Bolnike je treba oceniti glede na anamnezo preobčutljivosti na tienopiridine (na primer na klopidogrel, tiklopidin in prasugrel), ker so poročali o navzkrižnih alergijah med tienopiridini (glejte poglavje 4.8).
The concomitant administration of medicinal products associated with bleeding risk should be undertaken with caution (see section 4.4). 
V primeru sočasne uporabe zdravil, ki so povezana s tveganjem za krvavitve, je potrebna previdnost (glejte poglavje 4.4).
Ninety five patients (7%) in the guided de-escalation group and 118 patients (9%) in the control group (p non-inferiority=0.0004) had an event. 
- Enega od dogodkov je imelo 95 bolnikov (7 %) v skupini z vodeno deeskalacijo in 118 bolnikov (9 %) v kontrolni skupini (p za neinferiornost = 0,0004).
Rare side effects (may affect up to 1 in 1000 people): Vertigo, enlarged breasts in males. 
Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov): Vrtoglavica, povečanje prsi pri moških.
Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. 
CYP450 morajo presnoviti klopidogrel, da nastane aktivni presnovek, ki zavira agregacijo trombocitov.
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs), or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5). 
Tako kot druge antitrombotike tudi klopidogrel previdno uporabljamo pri bolnikih, pri katerih zaradi poškodbe, kirurškega posega ali drugih patoloških stanj obstaja tveganje za povečano krvavitev, in pri bolnikih, ki so na zdravljenju z ASA, s heparinom, z zaviralci glikoproteina IIb/IIIa ali z nesteroidnimi protivnetnimi zdravili (NSAIDs), vključno z zaviralci ciklooksigenaze-2 (COX-2), ali s selektivnimi zaviralci privzema serotonina (SSRI), ali z drugimi zdravili, ki so povezana s tveganjem za krvavitve, kot je pentoksifilin (glejte poglavje 4.5).
The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e. ST elevation, ST depression or left bundle-branch block). 
V študijo COMMIT s faktorsko raziskovalno zasnovo 2 x 2 je bilo v 24 urah po nastopu simptomov, ki bi lahko kazali na MI, vključenih 45.852 bolnikov z neustreznimi vrednostmi EKG, ki so to potrjevale (elevacija ST-spojnice, depresija ST-spojnice ali levokračni blok).
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Krka d.d. 
Če ste doživeli hudo obliko bolečine v prsih (nestabilna angina ali srčni napad), vam lahko zdravnik na začetku zdravljenja da enkratni odmerek po 300 mg zdravila Clopidogrel Krka d.d.
Therefore, the guided de-escalation arm had patients on either prasugrel (40%) or clopidogrel (60%). 
Zato so bili v skupini z vodeno deeskalacijo tako prejemniki prasugrela (40 %) kot prejemniki klopidogrela (60 %).
Major bleeding was mostly of extracranial origin in both groups (5.3% in the clopidogrel + ASA group; 3.5% in the placebo +ASA group), mainly from the gastrointestinal tract (3.5% vs. 1.8%). 
Hujše krvavitve so bile v obeh skupinah večinoma ekstrakranialne (5,3 % v skupini s klopidogrelom + ASA, 3,5 % v skupini s placebom + ASA), predvsem v prebavilih (3,5 % v prim.
75 mg film-coated tablets clopidogrel 
75 mg filmsko obložene tablete klopidogrel
with food and drink Clopidogrel Krka d.d. 
skupaj s hrano in pijačo Zdravilo Clopidogrel Krka d.d.
In patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). 
Bolniki z akutnim koronarnim sindromom - Akutni koronarni sindrom brez elevacije ST-spojnice (nestabilna angina ali miokardni infarkt brez Q-zobca): zdravljenje začnemo z enkratnim udarnim 300-mg odmerkom klopidogrela in nadaljujemo s 75-mg odmerkom enkrat na dan (75 mg do 325 mg ASA na dan).
Due to the risk of increased plasma concentrations, concomitant administration of clopidogrel and drugs primarily cleared by CYP2C8 metabolism (e.g., repaglinide, paclitaxel) should be undertaken with caution (see section 4.4). 
Zaradi tveganja za povečanje koncentracije v plazmi je potrebna previdnost med sočasno uporabo klopidogrela z zdravili, ki se odstranijo predvsem s presnovo s CYP2C8 (npr. repaglinid, paklitaksel) (glejte poglavje 4.4).
Intracranial bleeding (some cases were reported with fatal outcome), headache, paraesthesia, dizziness 
Bolezni živčevja intrakranialna krvavitev (opisani so primeri s motnje okusa, agevzija smrtnim izidom), glavobol, parestezije, omotica
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects'). 
- če razvijete bolezensko stanje (znano tudi kot trombotična trombocitopenična purpura ali TTP) z zvišano telesno temperaturo in modricami pod kožo, ki se lahko pojavijo kot drobne rdeče pike, z ali brez nerazložljive hude utrujenosti, zmedenosti, porumenele kože ali oči (zlatenica) (glejte poglavje 4 "Možni neželeni učinki").
As a precaution concomitant use of strong or moderate CYP2C19 inhibitors should be discouraged (see sections 4.4 and 5.2). 
Iz previdnosti naj sočasno ne bi uporabljali močnih ali srednje močnih zaviralcev CYP2C19 (glejte poglavji 4.4 in 5.2).
• Renal impairment Therapeutic experience is limited in patients with renal impairment (see section 4.4). 
- Okvara ledvic Terapevtske izkušnje pri bolnikih z okvaro ledvic so omejene (glejte poglavje 4.4).
After repeated doses of 75 mg clopidogrel per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects. 
Po večkratnem odmerjanju 75 mg klopidogrela na dan, ki je trajalo 10 dni, pri bolnikih s hudo jetrno okvaro je bilo zaviranje z ADP izzvane agregacije trombocitov podobno kot pri zdravih preiskovancih.
Musculo-skeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia 
Bolezni mišičnoskeletnega sistema in vezivnega tkiva mišično-skeletne krvavitve (hemartroza), artritis, artralgija, mialgija
Reproductive systems and breast disorders 
Motnje reprodukcije in dojk
The benefits observed with clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors). 
Koristi, ki so jih opazili pri zdravljenju s klopidogrelom, so bile neodvisne od drugih akutnih in dolgotrajnih srčno-žilnih terapij (npr. s heparinom ali nizkomolekulskim heparinom, antagonisti glikoproteinov IIb/IIIa, učinkovinami za zmanjševanje vrednosti lipidov, zaviralci adrenergičnih receptorjev beta in zaviralci angiotenzinske konvertaze).
Patients were randomized to receive either prasugrel 5 or 10 mg/d (Days 0-14) (n=1309), or prasugrel 5 or 10 mg/d (Days 0-7) then de-escalated to clopidogrel 75 mg/d (Days 8-14) (n=1309), in combination with ASA (<100 mg/day). 
Bolnike so randomizirali bodisi na prejemanje prasugrela 5 ali 10 mg/dan (od 0. do 14. dne) (n = 1309) bodisi na prejemanje prasugrela 5 ali 10 mg/dan (od 0. do 7. dne) s poznejšim deeskaliranjem na 75 mg klopidogrela na dan (od 8. do 14. dne) (n = 1309) v kombinaciji z ASA (< 100 mg/dan).
Therapeutic experience is limited in patients with moderate hepatic disease who may have bleeding diatheses (see section 4.4). 
Terapevtske izkušnje pri bolnikih z zmerno boleznijo jeter, ki imajo lahko hemoragično diatezo, so omejene (glejte poglavje 4.4).
If you become pregnant while taking Clopidogrel Krka d.d., consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant. 
zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
Therefore, concomitant use of clopidogrel with boosted ART should be discouraged. 
Zato se sočasna uporaba klopidogrela in okrepljenega protiretrovirusnega zdravljenja odsvetuje.
Very rare side effects (may affect up to 1 in 10,000 people): jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); swelling in the mouth; blisters of the skin; skin allergy; sore mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in taste or loss of taste of food. 
Zlatenica, huda bolečina v trebuhu z bolečino v hrbtu ali brez nje, zvišana telesna temperatura, težave pri dihanju, ki so včasih povezane s kašljem, splošne alergijske reakcije (na primer, splošni občutek toplote z nenadnim nelagodjem do nezavesti), oteklina v ustih, mehurji na koži, kožna alergija, vnetje v ustih (stomatitis), znižanje krvnega tlaka, zmedenost, halucinacije, bolečine v sklepih, bolečine v mišicah, motnje v okušanju ali izguba okusa hrane.
Other medicines and Clopidogrel Krka d.d. 
Druga zdravila in zdravilo Clopidogrel Krka d.d.
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)). 
Bolnikov s primarnim opazovanim dogodkom (srčno-žilna smrt, MI ali možganska kap) je bilo v skupini, zdravljeni s klopidogrelom, 582 (9,3 %), v placebo skupini pa 719 (11,4 %), kar pomeni 20odstotno zmanjšanje RT (95-odstotni IZ: 10-28 %; p = 0,00009) v skupini, ki se je zdravila s klopidogrelom (17-odstotno zmanjšanje RT, če so bili bolniki zdravljeni konzervativno, 29-odstotno, če je bila izvedena perkutana transluminalna koronarna angioplastika (PTCA) z žilno opornico ali brez nje, in 10-odstotno, če je bila izvedena premostitvena operacija koronarnih arterij (CABG).
(98.1%) in the de-escalated DAPT group and 318 patients (98.5%) in the unchanged DAPT group. 
Enoletno spremljanje je bilo opravljeno pri 316 bolnikih (98,1 %) v skupini z deeskaliranim DAPT in pri 318 bolnikih (98,5 %) v skupini z nespremenjenim DAPT.
Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised. 
Bolnike z znano alergijo na tienopiridine je priporočljivo kontrolirati glede znakov preobčutljivosti.
Your doctor should have prescribed Clopidogrel Krka d.d. 
Zdravnik naj bi vam predpisal zdravilo Clopidogrel Krka d.d.
- You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack). 
- ste doživeli hudo obliko bolečine v prsih (nestabilna angina ali srčni napad).
Patients received clopidogrel (75 mg/day, n=22,961) or placebo (n=22,891), in combination with ASA (162 mg/day), for 28 days or until hospital discharge. 
Bolniki so 28 dni oziroma do odpusta dobivali klopidogrel (75 mg na dan, n = 22.961) ali placebo (n=22.891) v kombinaciji z ASA (162 mg na dan).
Acute liver failure, hepatitis, abnormal liver function test 
Bolezni jeter, žolčnika in žolčevodov akutna odpoved jeter, hepatitis, nenormalni testi jetrne funkcije
• Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time. 
Če bolnik izpusti odmerek: - če je zamuda manj kot 12 ur po pravem času: bolnik naj odmerek vzame takoj, potem pa naslednji odmerek ob pravem času.
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, eosinophilic pneumonia 
Bolezni dihal, prsnega koša in mediastinalnega prostora epistaksa krvavitve v dihalih (hemoptiza, pljučna krvavitev), bronhospazem, intersticijski pnevmonitis, eozinofilna pljučnica